The complex [Cr(tpy)(O3SCF3)3] (tpy = 2,2':6',2''-terpyridine) is readily made from [Cr(tpy)Cl3] and is a convenient precursor to [Cr(tpy)2][PF6]3 and to [Cr(tpy)(4'-(4-tolyl)tpy)][PF6]3 and [Cr(tpy)(5,5''-Me2tpy)][PF6]3 (4'-(4-tolyl)tpy = 4'-(4-tolyl)-2,2':6',2''-terpyridine; 5,5''-Me2tpy = 5,5''-dimethyl-2,2':6',2''-terpyridine); these are the first examples of heteroleptic bis(tpy) chromium(III) complexes. The single crystal structures of 2{[Cr(tpy)2][PF6]3}·5MeCN, [Cr(tpy)(4'-(4-tolyl)tpy)][PF6]3·3MeCN and [Cr(tpy)(5,5''-Me2tpy)][PF6]3·3MeCN have been determined. Each cation contains the expected octahedral {Cr(tpy)2}(3+) unit; in all three structures, the need to accommodate three anions per cation and the solvent molecules prevents the formation of a grid-like array of cations that is typical of many lattices containing {M(tpy)2}(2+) motifs. Three reversible electrochemical processes are observed for [Cr(tpy)(4'-(4-tolyl)tpy)][PF6]3 and [Cr(tpy)(5,5''-Me2tpy)][PF6]3, consistent with those documented for [Cr(tpy)2](3+). At pH 6.36, aqueous solutions of [Cr(tpy)2][PF6]3 are stable for at least two months. However, contrary to the expectations of the d(3) Cr(3+) ion being a kinetically inert metal centre, the tpy ligands in [Cr(tpy)2](3+) are labile in the presence of base; absorption and (1)H NMR spectroscopies have been used to monitor the effects of adding NaOH to aqueous and CD3OD solutions, respectively, of the homo- and heteroleptic complexes. Ligand dissociation is also observed when [Bu4N]F is added to CD3OD solutions of the complexes, but in aqueous solution, [Cr(tpy)2][PF6]3 is stable in the presence of fluoride ion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.